Literature DB >> 10975473

Therapeutic apheresis in myasthenia gravis.

A P Batocchi1, A Evoli, C Di Schino, P Tonali.   

Abstract

Plasma exchange (PE) is an easily applicable technique for rapid and massive removal of antibodies, and its beneficial role is well established in the management of myasthenia gravis (MG), an antibody-mediated disorder of the neuromuscular junction. PE is useful in myasthenic crisis, in most severe forms of MG before thymectomy, in the early postoperative period, and in cases of symptom worsening during tapering or initiation of immunosuppressive therapy. Clinical efficacy varies from 55% to 100%, and improvement rarely persists for more than 4-10 weeks; thus immunosuppressive therapy has to be associated. New apheretic techniques (double filtration plasmapheresis, immunoadsorption systems with staphylococcal protein A columns or thryptophan-polyvinyl alcohol gel columns) that allow the selective removal of IgG and anti-AChR antibody were recently used in the management of MG with positive effects. Whether their therapeutic effect and cost effect prove more favorable than those obtained by PE still must be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975473     DOI: 10.1046/j.1526-0968.2000.004004275.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  9 in total

Review 1.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.

Authors:  Enrique Gomez-Figueroa; Sofía Garcia-Trejo; Lisette Bazan-Rodriguez; Roberto Cervantes-Uribe; German Chac-Lezama; Juan Carlos López-Hernández; Steven Vargas-Cañas
Journal:  J Neurol       Date:  2019-11-12       Impact factor: 4.849

4.  Construction of a functional S-layer fusion protein comprising an immunoglobulin G-binding domain for development of specific adsorbents for extracorporeal blood purification.

Authors:  Christine Völlenkle; Stefan Weigert; Nicola Ilk; Eva Egelseer; Viktoria Weber; Fritz Loth; Dieter Falkenhagen; Uwe B Sleytr; Margit Sára
Journal:  Appl Environ Microbiol       Date:  2004-03       Impact factor: 4.792

Review 5.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

6.  Myasthenia gravis: a review.

Authors:  Annapurni Jayam Trouth; Alok Dabi; Noha Solieman; Mohankumar Kurukumbi; Janaki Kalyanam
Journal:  Autoimmune Dis       Date:  2012-10-31

7.  Treatment of myasthenia gravis based on its immunopathogenesis.

Authors:  Jee Young Kim; Kee Duk Park; David P Richman
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

8.  Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.

Authors:  Gregory Kordas; George Lagoumintzis; Sotirios Sideris; Konstantinos Poulas; Socrates J Tzartos
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

Review 9.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.

Authors:  Ashley Y Choi; Miriam Manook; Danae Olaso; Brian Ezekian; Jaeberm Park; Kyle Freischlag; Annette Jackson; Stuart Knechtle; Jean Kwun
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.